A few days ago the The United Kingdom warned on an unexpected effect associated with the use of Ozempic and treatments based on the same principle, the phenomenon of Ozempic Babies. Now the Spanish Agency for Medicines and Health Products (AEMPS) has also issued a statement but this time as a consequence of a very different effect.
Adverse reaction. This week the AEMPS, the agency in charge of ensuring that the drugs meet the required standards, has issued A statement To warn of a very uncommon ocular adverse reaction “associated with treatments based on the semaglutida, the active compound of drugs such as Ozempic, Rybelsus or Wegovy.
The notice occurs after the Committee for the Risk Assessment in Pharmacovigilance (PRAC) of the European Medication Agency (EMA) reviewed the risk of developing an ocular condition called Niana, which can cause loss of sudden vision.
While the agency affects that the frequency of appearance of this type of eye problems is “very low”, it recommends that a sudden loss of vision is carried out an ophthanmological examination for Evaluate the possibility to interrupt the treatment.
Noiana. Noiana is an acronym that refers to calls Previous ischemic optical neuropathiesNaion in English. These ailments are caused For the infarction of the optic nerve head. In other words, blood does not reach this eye region and a loss of vision occurs, which is typically fast but painless.
It is an unknown and infrequent disease, not only in the context of those who follow a trailer treatment: its prevalence in the general population is approximately 10 cases per 100,000 inhabitants.
A year on track. A year agoa study I found indications of the relationship between the treatments of Semaglutida and Niana. Indications such as those that gave rise to the evaluation by the Pract. The Committee reviewed clinical and preclinical essay data together with suspicion of adverse reactions, explains the AEMPS.
This work resulted in the conclusion that trailer treatment can be associated with a risk of developing this disorder but indicate that with a very low frequency. The AEMPS speaks of “an increase in the risk of developing Niana of approximately double compared to people not exposed to this treatment. This corresponds to an additional case of NOIANA for every 10,000 patients treated with semagglutida for a year.”
And what about the “other ozempic”? The AEMPS statement focuses on the drug -based drugs such as Ozempic, Rybelsus and Wegovy but does not indicate whether similar effects have been detected on similar treatments such as those based on the tirzepatida, such as Zepbound and Mounjaro.
A medication with side effects. Like any drug, the semaglutida has a series of Contraindications and side effects. It should be remembered in this sense that the success of drugs such as Ozempic began when it was observed that this treatment against diabetes made those who followed it lost weight.
Image | Chemist4u / Amanda Dalbjörn
GIPHY App Key not set. Please check settings